glp-1 cardiovascular outcomes trial results august 2025 Efficacy of GLP‐1 Receptor Agonist‐Based Therapies on Events and Cardiometabolic Parameters in Obese Individuals Without Diabetes: A Meta‐Analysis of Randomized Controlled Trials - Yin - Kidney and Cardiovascular Outcomes Among

9 BateA.LindquistM.EdwardsI

This narrative review outlines the rationale for their use in KTRs, drawing from recent trials in non-transplant populations and emerging real-world evidence in KTR We recommend reading this article

When the Free Version Is Not Enough If you want to photograph meals instead of scanning or searching, want milestone Journey Cards built from your progress photos, want your protein, water, and shot countdown on the home screen without opening the app, or find yourself leaning on Capy past the free allowance, that is what the premium subscription is for

Iron deficiency develops in a meaningful percentage of patients on GLP-1 receptor agonists like semaglutide, often appearing 3-6 months into treatment